
    
      This is a multi-centre, prospective, open label, non-comparative phase IV trial. Eligible
      patients will receive treatment with IFN-beta-1a AVONEXÂ® 30 mcg i.m. once weekly for 12
      months.The patients will be examined clinically and NAb titres will be performed at screening
      and after 12 months. Adverse event source verification will be performed during the
      documentation period.
    
  